Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms

Chinese Medical Sciences Journal

Volumn 20, Issue 1, 2005, Pages 44-47

  Wan, Xin Hua ^a   Vuong, Kevin Dat ^b   Jankovic, Joseph ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Botulinum toxin type B; Movement disorders; Sialorrhea

Indexed keywords

BOTULINUM TOXIN B;

ARTICLE; AUTONOMIC DYSFUNCTION; BLEPHAROSPASM; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; DYSTONIA; FOLLOW UP; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PAIN; PTOSIS; RETROSPECTIVE STUDY; TIC; TREMOR; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BLEPHAROSPASM; BOTULINUM TOXINS; FOLLOW-UP STUDIES; HUMANS; HYPERHIDROSIS; INJECTIONS; MEIGE SYNDROME; MOVEMENT DISORDERS; RETROSPECTIVE STUDIES; SIALORRHEA; TORTICOLLIS;

EID: 16844376232     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-8.
2. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
3. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46.
4. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type-A resistant cervical dystonia. Neurology 1999;53:1431-8.
5. Parish JL. Commercial preparations and handling of botulinum toxin type A and type B. Clin Dermatol 2003;21:481-4.
6. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-9.
7. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.
8. Colosimo C, Chianese M, Giovannelli M, et al. Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol Neurosurg Psychiatry 2003;74:687.
9. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002;62:705-22.
10. Baumann L, Black L. Botulinum toxin type B (Myobloc). Dermatol Surg 2003;29:496-500.
11. Tintner R, Winzer UF, Smalky KA, et al. A double-blind, randomized, parallel group design comparison of botulinum toxin, type a (Botox®) and botulinum toxin, type b (Myobloc™) on autonomic symptoms and physiology in patients with cervical dystonia. Neurology 2004;62(Suppl 5):A538.
12. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-8.
13. Dressier D. Botulinum toxin type B: Where do we stand? Eur Neurol 2001;46:113-4.
14. Stacy M. Treatment of limb dystonia with botulinum toxin type B. Mov Disord 2002;17(Suppl 5):P1016.
15. Aoki KR. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 2002;40:923-8.
16. Atassi MZ. Immune recognition and cross-reactivity of botulinum neurotoxins. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of Botulinum toxin. Philadelphia: Lippincott Williams & Wilkins;2002.p.285-408.
17. Dressler D, Bigalke H, Benecke R Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003;250:1263-5.